Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Current Hematologic Malignancy Reports|May 13, 2021
Progress in the Management of Smoldering Multiple MyelomaTimothy M Schmidt, Natalie S CallanderBlood Cancer Journal|April 30, 2021
Chromosome 1q21 abnormalities in multiple myelomaTimothy M Schmidt, Rafael Fonseca, Saad Z UsmaniLeukemia & Lymphoma|September 28, 2022
Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapySusan Bal, Timothy M Schmidt, Luciano J Costa, et al.Anticancer Research|July 5, 2018
Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular CarcinomaTimothy M Schmidt, L I Liu, Ivy E Abraham, et al.Transplantation and Cellular Therapy|November 15, 2023
PD1+TIGIT+2B4+KLRG1+ Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell TherapyAmeet K Mishra, Timothy M Schmidt, Ella B Martell, et al.Journal of Computer Assisted Tomography|October 23, 2025
Rapid PET/MRI to Assess Multiple Myeloma Using T2-Weighted Imaging With Uniform Fat SuppressionRianne A van der Heijden, Timothy M Schmidt, Lu Mao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple MyelomaLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.American Journal of Hematology|June 22, 2022
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapySusan Bal, Binod Dhakal, Rebecca W Silbermann, et al.The Lancet. Haematology|September 30, 2023
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trialLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.Blood Cancer Journal|November 27, 2019
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasoneTimothy M Schmidt, Benjamin G Barwick, Nisha Joseph, et al.Pageof 2